Skip to content

A Comparative Clinical Study of Kalmeghanavayasa Lauha and Arogyavardhini Vati in the Management of Fatty Liver Disease (MAFLD)

A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF KALMEGHANAVAYASA LAUHA AND AROGYAVARDHINI VATI IN YAKRIT ROGA WITH SPECIAL REFERENCE TO MAFLD - NIL

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100886
Enrollment
60
Registered
2026-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E788- Other disorders of lipoprotein metabolism

Interventions

None listed

Sponsors

National Institute of Ayurveda, Deemed to be university, Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex male or female 2. Age group equal and more then18 years and equal and less then 60 years 3. USG finding suggestive of fatty liver grade 1 and 2. 4.Clinical sign and symptoms suggesting of Yakrita Roga that Aruchi ,Daurablya, Avipak,Aadhman, Vibandh. 5.Willingness to participate in the study and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women. 2.Patients with history of autoimmune hepatitis, drug abuse, Acute and chronic hepatitis. 3. Patients with complications of metabolic syndrome such as cerebrovascular accident, myocardial infarction, chronic kidney diseases, suffering from cirrhosis, ascites, variceal haemorrhage, coagulopathy, hepatorenal syndrome. 4. Patient having blood pressure 160/90 mm of Hg and more according JNC-8 . 5.Patient of DM type 1 (IDDM). 6.Patients not willing to fill consent forms.

Design outcomes

Primary

MeasureTime frame
Change in USG grading of fatty liver from baseline to the end of the treatment period.Timepoint: Baseline , 30th day ,60th day ,end of treatment period.

Secondary

MeasureTime frame
To change in the intensity of the symptoms associated with Yakrit roga , and LFT , RFT, CBC, FBS HbA1C,ESR comparative effect of these two drugsTimepoint: Baseline , 30th day ,60th day ,end of treatment

Countries

India

Contacts

Public ContactDr Ajay Kumar Sahu

National institute of Ayurveda, Jaipur

drajaysahu@gmail.com9950708106

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026